Par Health Launches First and Only Generic Version of Janumet XR in the United States

Corporate Action
โดย PR Newswire·Read original
Summary · why it matters

Par Health has launched the first and only FDA-approved generic version of Merck's Janumet XR tablets in the United States. The product, sitagliptin and metformin HCl extended-release tablets, received final approval from the U.S. Food and Drug Administration. According to IQVIA data, Janumet XR had estimated annual U.S. sales of approximately $269.9 million for the 12 months ended May 2026. Jake Longenecker, Executive Vice President and Chief Commercial Officer of Generics at Par Health, said the first-to-market generic helps expand access to more affordable treatment options.

Impact on stocks 2

Biotech & Genomic Medicine▼ · 1 stocks
Merck & Company Inc
MRK
▼ NegativeCompetitionrelevance

Par Health launches first generic of Merck's Janumet XR, eroding Merck's market share.

Critical Materials & Supply Chain▲ · 1 stocks

Off-coverage companies 1

Par Health, Inc.Private▲ Positive
Demandrelevance

Par Health launches first generic of Janumet XR, capturing $269.9M market.

© 2026 MarketDXNews